263 related articles for article (PubMed ID: 18332304)
1. Low-dose rosiglitazone in patients with type 2 diabetes mellitus requiring insulin therapy.
Lopez CA; Kanna B
Arch Intern Med; 2008 Mar; 168(5):548. PubMed ID: 18332304
[No Abstract] [Full Text] [Related]
2. Low-dose rosiglitazone in patients with insulin-requiring type 2 diabetes.
Hollander P; Yu D; Chou HS
Arch Intern Med; 2007 Jun; 167(12):1284-90. PubMed ID: 17592102
[TBL] [Abstract][Full Text] [Related]
3. Reductions in biomarkers of cardiovascular risk in type 2 diabetes with rosiglitazone added to metformin compared with dose escalation of metformin: an EMPIRE trial sub-study.
Goldstein BJ; Weissman PN; Wooddell MJ; Waterhouse BR; Cobitz AR
Curr Med Res Opin; 2006 Sep; 22(9):1715-23. PubMed ID: 16968575
[TBL] [Abstract][Full Text] [Related]
4. A randomized, controlled trial of the effects of rosiglitazone on adipokines, and inflammatory and fibrinolytic markers in diabetic patients: study design and protocol.
Gupta M; Braga MB; Verma S
Can J Cardiol; 2008 Oct; 24(10):e65-9. PubMed ID: 18841263
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the glycemic effects of rosiglitazone and pioglitazone in triple oral therapy in type 2 diabetes.
Tran MT; Navar MD; Davidson MB
Diabetes Care; 2006 Jun; 29(6):1395-6. PubMed ID: 16732030
[No Abstract] [Full Text] [Related]
6. Do patients with type 2 diabetes on peritoneal dialysis need less insulin if they are given rosiglitazone?
Scherbaum WA
Nat Clin Pract Nephrol; 2006 Jun; 2(6):312-3. PubMed ID: 16932451
[No Abstract] [Full Text] [Related]
7. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.
Rosenstock J; Sugimoto D; Strange P; Stewart JA; Soltes-Rak E; Dailey G
Diabetes Care; 2006 Mar; 29(3):554-9. PubMed ID: 16505505
[TBL] [Abstract][Full Text] [Related]
8. Rosiglitazone in combination with glimepiride plus metformin in type 2 diabetic patients.
Kiayias JA; Vlachou ED; Theodosopoulou E; Lakka-Papadodima E
Diabetes Care; 2002 Jul; 25(7):1251-2. PubMed ID: 12087036
[No Abstract] [Full Text] [Related]
9. Combined pioglitazone and metformin treatment maintains the beneficial effect of short-term insulin infusion in patients with type 2 diabetes: results from a pilot study.
Musholt PB; Schöndorf T; Pfützner A; Hohberg C; Kleine I; Fuchs W; Hehenwarter S; Dikta G; Kerschgens B; Forst T
J Diabetes Sci Technol; 2009 Nov; 3(6):1442-50. PubMed ID: 20144400
[TBL] [Abstract][Full Text] [Related]
10. Rosiglitazone improves endothelial function in patients with type 2 diabetes treated with insulin.
Naka KK; Papathanassiou K; Bechlioulis A; Pappas K; Kazakos N; Kanioglou C; Papafaklis MI; Kostoula A; Vezyraki P; Makriyiannis D; Tsatsoulis A; Michalis LK
Diab Vasc Dis Res; 2011 Jul; 8(3):195-201. PubMed ID: 21576196
[TBL] [Abstract][Full Text] [Related]
11. Clinical research observations with use of exubera in patients with type 1 and 2 diabetes.
Cefalu WT; Wang ZQ
Diabetes Technol Ther; 2007 Jun; 9 Suppl 1():S28-40. PubMed ID: 17563301
[No Abstract] [Full Text] [Related]
12. Addition of biphasic insulin aspart 30 to rosiglitazone in type 2 diabetes mellitus that is poorly controlled with glibenclamide monotherapy.
Raz I; Mouritzen U; Vaz J; Hershkovitz T; Wainstein J; Harman-Boehm I
Clin Ther; 2003 Dec; 25(12):3109-23. PubMed ID: 14749149
[TBL] [Abstract][Full Text] [Related]
13. Thiazolidinediones increase hepatic insulin extraction in African Americans with impaired glucose tolerance and type 2 diabetes mellitus. A pilot study of rosiglitazone.
Osei K; Gaillard T; Schuster D
Metabolism; 2007 Jan; 56(1):24-9. PubMed ID: 17161222
[TBL] [Abstract][Full Text] [Related]
14. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.
Fonseca V; Rosenstock J; Patwardhan R; Salzman A
JAMA; 2000 Apr; 283(13):1695-702. PubMed ID: 10755495
[TBL] [Abstract][Full Text] [Related]
15. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.
Derosa G; D'Angelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Montagna L; Gravina A; Ferrari I; Paniga S; Cicero AF
J Clin Pharm Ther; 2006 Aug; 31(4):375-83. PubMed ID: 16882108
[TBL] [Abstract][Full Text] [Related]
16. Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome.
Derosa G; Gaddi AV; Piccinni MN; Ciccarelli L; Salvadeo S; Peros E; Ghelfi M; Ferrari I; Cicero AF
Pharmacotherapy; 2005 May; 25(5):637-45. PubMed ID: 15899724
[TBL] [Abstract][Full Text] [Related]
17. Metformin, but not rosiglitazone, attenuates the increasing plasma levels of a new cardiovascular marker, fibulin-1, in patients with type 2 diabetes.
Skov V; Cangemi C; Gram J; Christensen MM; Grodum E; Sørensen D; Argraves WS; Henriksen JE; Rasmussen LM
Diabetes Care; 2014; 37(3):760-6. PubMed ID: 24135389
[TBL] [Abstract][Full Text] [Related]
18. Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and rosiglitazone or insulin and acarbose in type 2 diabetes.
Yilmaz H; Gursoy A; Sahin M; Guvener Demirag N
Acta Diabetol; 2007 Dec; 44(4):187-92. PubMed ID: 17726570
[TBL] [Abstract][Full Text] [Related]
19. Short-term continuous subcutaneous insulin infusion combined with insulin sensitizers rosiglitazone, metformin, or antioxidant α-lipoic acid in patients with newly diagnosed type 2 diabetes mellitus.
Huang Z; Wan X; Liu J; Deng W; Chen A; Liu L; Liu J; Wei G; Li H; Fang D; Li Y
Diabetes Technol Ther; 2013 Oct; 15(10):859-69. PubMed ID: 23991629
[TBL] [Abstract][Full Text] [Related]
20. Effect of short-term rosiglitazone therapy in peritoneal dialysis patients.
van Hooland S; Boey O; Van der Niepen P; Van den Branden C; Verbeelen D
Perit Dial Int; 2009; 29(1):108-11. PubMed ID: 19164260
[No Abstract] [Full Text] [Related]
[Next] [New Search]
